CSI Market
Sign In | Register

Orchard Therapeutics Plc (ORTX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ORTX Annual Cash Flow →
A period-by-period view of cash flow from Orchard Therapeutics Plc to Sep 30 2022 helps clarify how Sep 30 2023's cash position has changed over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2023)
9 Months 		(Jun 30 2023) (Mar 31 2023) (Dec 31 2022) (Sep 30 2022)
Operating Activities
Income-35.32
Depreciation & amortization1.95
Amortization of Other Assets0.10
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Asset Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-3.27
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation2.47
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants-3.26
Amortization Of Provision On Loss Contract-2.90
Non Cash Consideration For Licenses And Milestones-
Change In Fair Value Of Tranche Obligation Liability-
Non Cash Interest Expense0.27
Non Cash Consideration For Licenses-
Accretion Of Discount On Marketable Securities-
Increase Decrease In Research And Development Tax Credit Receivable-5.76
Increase Decrease In Operating Right Of Use Assets3.36
Amortization Of Premium And Discounts On Marketable Securities-
Amortization Of Premium On Marketable Securities-
Unrealized Foreign Currency And Other Non Cash Adjustments-3.18
Increase Decrease In Operating Lease Liabilities-4.03
Income taxes1.13
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable2.40
Increase (Decrease) in Accounts Payable0.00
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.25
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-11.21
Discontinued operations0.00
Net Cash flow from Operating Activities-81.23
Investing Activities
Capital Expenditures-0.61
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities122.82
Payments to Acquire Available-for-sale Securities, Debt-146.67
Real Estate Investments0.00
Receipt Of Funds From Construction Deposit-
Payments to Acquire Restricted Certificates of Deposit0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-24.46
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-7.07
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock67.34
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issuance Of Follow On Offering Net Of Offering Cost-
Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction-
Capital Expenditures Incurred But Not Yet Paid-
Right Of Use Asset Obtained In Exchange For Operating Lease Liability-
Stock Issued-
Proceeds From Issuance Follow On Offering Net Of Underwriters Discounts-
Payment Of Taxes On Net Settlement Of Equity Plan Issuances-
Proceeds From Issuance Of Shares As Part Of Collaboration Agreement-
Payment Of Taxes On Restricted Stock Vesting-0.18
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities60.09
Effect of exchange rate on cash flow0.65
Discontinued operations0.00
Free Cash Flow-81.84
Total Cash Flow-44.96
4 historic quarters locked

Sign in to unlock the full Orchard Therapeutics Plc cash flow history.

Sign In Create Free Account

About Orchard Therapeutics Plc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-23-062428

Figures are derived from filed reports and may be restated. Historical data is subject to revision.